Of the total sum, RON115 million is earmarked for cofinancing the investment objective “Production, packaging and storage capacity for sterile products, solutions and topicals” which is the subject of the Financing Agreement no. 538/17.05.2023 of the Ministry of Finance.
Antibiotice analyzed the most efficient of the three banking offers received from UniCredit Bank, Alpha Bank and the European Investment Bank. The EIB offer, involving the lowest multiannual costs, was selected.
Antibiotice ended the first half of 2023 with RON315.9 million, up 27% against 1H/2022, while net profit rose by 82.8% to RON62 million.
The company’s shares have added 112% this year amid deals worth RON30.6 million. The state-owned company is valued at RON800 million.
(English version by Catalina Apostoiu)